Presence & RecognitionEvent: September 8, 2026
Nuvisan is attending CPHI Milan 2026 to discuss small molecule API/HPAPI process development, analytical support, formulation, clinical manufacturing, clinical trial supply, and EU QP release alongside colleagues from ALS.
Published
Signal category
Presence & Recognition
Quote
“Together with our colleagues from ALS, we will be at CPHI Milan 2026 to discuss how our combined capabilities can support your next development milestone and serve you across the entire value chain.”
— Nuvisan team
Company
Nuvisan
From discovery to the clinic and beyond
- Industry
- Biotechnology Research
- Location
- Neu-Ulm, DE
- Company size
- 641 employees
Your partner of choice in bringing therapeutics to life, Nuvisan is the unique CRO/CDMO with extensive pharma experience and industry-leading scientific expertise, providing highest-quality end-to-end solutions. From enabling target understanding to helping get innovative medicines to the patients who need them, we provide support that streamlines and accelerates drug discovery and development.